CY1111237T1 - Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης - Google Patents

Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης

Info

Publication number
CY1111237T1
CY1111237T1 CY20101101132T CY101101132T CY1111237T1 CY 1111237 T1 CY1111237 T1 CY 1111237T1 CY 20101101132 T CY20101101132 T CY 20101101132T CY 101101132 T CY101101132 T CY 101101132T CY 1111237 T1 CY1111237 T1 CY 1111237T1
Authority
CY
Cyprus
Prior art keywords
treatment
primpexolis
self
automatic laboratory
laboratory science
Prior art date
Application number
CY20101101132T
Other languages
Greek (el)
English (en)
Inventor
James P Bennett Jr
Original Assignee
University Of Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Virginia Patent Foundation filed Critical University Of Virginia Patent Foundation
Publication of CY1111237T1 publication Critical patent/CY1111237T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Artificial Filaments (AREA)
  • Noodles (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20101101132T 2001-12-11 2010-12-08 Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης CY1111237T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33938301P 2001-12-11 2001-12-11
US34737102P 2002-01-11 2002-01-11
EP02795869A EP1453505B1 (en) 2001-12-11 2002-12-02 Use of pramipexole to treat amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CY1111237T1 true CY1111237T1 (el) 2015-06-11

Family

ID=26991607

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101101132T CY1111237T1 (el) 2001-12-11 2010-12-08 Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης

Country Status (19)

Country Link
US (4) US7157480B2 (https=)
EP (4) EP1453505B1 (https=)
JP (2) JP4500543B2 (https=)
KR (1) KR20040066890A (https=)
CN (1) CN1617720A (https=)
AT (1) ATE480235T1 (https=)
AU (1) AU2002360600B2 (https=)
CA (1) CA2468747C (https=)
CY (1) CY1111237T1 (https=)
DE (1) DE60237635D1 (https=)
DK (1) DK1453505T3 (https=)
ES (2) ES2432527T3 (https=)
HU (1) HUP0500001A3 (https=)
IL (1) IL162408A0 (https=)
MX (1) MXPA04005572A (https=)
PL (1) PL374310A1 (https=)
PT (1) PT1453505E (https=)
RU (1) RU2004121177A (https=)
WO (1) WO2003049705A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US20080262053A1 (en) * 2005-10-18 2008-10-23 Juergen Reess Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls)
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) * 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
EP2497473A1 (en) * 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and pharmaceutical compositions thereof
AU2016210640B2 (en) * 2006-12-14 2018-02-22 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
DK2101766T3 (en) * 2006-12-14 2017-01-16 Knopp Biosciences Llc Compositions and Methods for Using (R) -Pramipexole
AU2013209376B2 (en) * 2006-12-14 2016-05-05 Knopp Biosciences Llc Compositions and methods of using (r)-pramipexole
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
JP2010521493A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． （６ｒ）−４，５，６，７−テトラヒドロ−ｎ６−プロピル−２，６−ベンゾチアゾール−ジアミンの放出調節製剤およびそれらの使用方法
GB0811642D0 (en) * 2008-06-25 2008-07-30 Univ Edinburgh Assay
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
EP2887954B1 (en) 2012-08-23 2020-05-06 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions
US10874669B2 (en) 2012-11-29 2020-12-29 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
WO2014085600A1 (en) * 2012-11-29 2014-06-05 Wayne State University Neuroprotective agents for treatment of neurodegenerative diseases
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3838271B1 (en) 2013-07-12 2025-09-03 Areteia Therapeutics, Inc. Treating elevated levels of eosinophils and/or basophils
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2019049145A1 (en) 2017-09-11 2019-03-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. COMPOSITIONS AND METHODS FOR NASAL BRAIN MEDICATION ADMINISTRATION FOR SYSTEMIC EFFECT

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US560420A (en) 1896-05-19 Steam and oil separator
DE3447075A1 (de) * 1984-12-22 1986-07-03 Dr. Karl Thomae Gmbh, 7950 Biberach Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
ATE45735T1 (de) * 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
JP3468526B2 (ja) * 1995-10-26 2003-11-17 サノフィーサンテラボ 筋萎縮性側索硬化症治療薬調製のための１−（２−ナフタ−２−イルエチル）−４−（３−トリフルオロメチルフェニル）−１，２，３，６−テトラヒドロピリジンの使用
GB9705428D0 (en) * 1997-03-15 1997-04-30 Knoll Ag Therapeutic agents
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
PE20000728A1 (es) * 1998-06-26 2000-08-21 Cocensys Inc Heterociclos 4-bencil piperidina alquilsulfoxido y su uso como antagonistas receptores subtipo-selectivo nmda
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
WO2000006162A1 (de) * 1998-07-27 2000-02-10 Boehringer Ingelheim Pharma Kg Mittel mit antidepressiver wirkung, mit pramipexol und einem weiteren antidepressivum
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
DE19938825A1 (de) 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
AU7620600A (en) 1999-09-30 2001-04-30 General Hospital Corporation, The Use of pramipexole as a treatment for cocaine craving
PE20011074A1 (es) 2000-02-23 2001-10-04 Upjohn Co Uso de pramipexol en el tratamiento de trastornos de adiccion
AU2001278875B2 (en) * 2000-07-06 2007-06-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tetrahydrobenzothiazole analogues as neuroprotective agents
DE10037619A1 (de) * 2000-08-02 2002-02-14 Daimler Chrysler Ag Anordnung von Bedienelementen
ES2187249B1 (es) * 2000-09-18 2004-09-16 Synthon Bv Procedimiento para la preparacion de 2-amino-6-(alquil)amino-4,5,6,7-tetrahidrobenzotiazoles.
AU2001296703A1 (en) * 2000-10-06 2002-04-15 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
DE10137082A1 (de) * 2001-07-28 2003-02-13 Hexal Ag Matrixkontrolliertes transdermales therapeutisches System zur Anwendung von Pramiprexol und Ropinirol
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
WO2003077902A1 (en) * 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
WO2005010011A2 (en) * 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
WO2007022182A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole

Also Published As

Publication number Publication date
EP1453505A4 (en) 2007-01-10
JP2010031059A (ja) 2010-02-12
JP4500543B2 (ja) 2010-07-14
ES2432527T3 (es) 2013-12-04
US20050032856A1 (en) 2005-02-10
PT1453505E (pt) 2010-12-16
IL162408A0 (en) 2005-11-20
KR20040066890A (ko) 2004-07-27
JP2005516911A (ja) 2005-06-09
AU2002360600A1 (en) 2003-06-23
US7157480B2 (en) 2007-01-02
US20110301210A1 (en) 2011-12-08
EP2246053B1 (en) 2013-09-18
DK1453505T3 (da) 2010-11-15
DE60237635D1 (de) 2010-10-21
PL374310A1 (en) 2005-10-03
EP1453505B1 (en) 2010-09-08
US20070105918A1 (en) 2007-05-10
EP2305253A1 (en) 2011-04-06
EP1453505A2 (en) 2004-09-08
CA2468747A1 (en) 2003-06-19
CA2468747C (en) 2011-05-31
ES2351303T3 (es) 2011-02-02
WO2003049705A2 (en) 2003-06-19
HK1150153A1 (en) 2011-11-04
MXPA04005572A (es) 2004-12-06
RU2004121177A (ru) 2005-03-10
EP2246053A1 (en) 2010-11-03
US20130172394A1 (en) 2013-07-04
HUP0500001A3 (en) 2005-11-28
HUP0500001A2 (hu) 2005-04-28
ATE480235T1 (de) 2010-09-15
CN1617720A (zh) 2005-05-18
EP2305252A1 (en) 2011-04-06
AU2002360600B2 (en) 2007-11-29
WO2003049705A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
CY1111237T1 (el) Χρηση πραμιπεξολης για αντιμετωπιση αμυοτροφικης πλευρικης σκληρυνσης
TR200400815T3 (tr) AtorvastatinÁyarı@kalsiyumunÁyeniÁkristalÁformlarıÁveÁbunlarınÁhazırlanmasıÁiçinÁişlemlerÁayrıcaÁdiğerÁformlarınÁhazırlanmasıÁiçinÁyeniÁişlemler
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
CY1111613T1 (el) Μεθοδοι για την αντιμετωπιση της μολυνσης απο hiv
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1116992T1 (el) Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
CY1106032T1 (el) Υποκατασταθεισες πυραζολες
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
CY1110604T1 (el) Συνδυασμος αναστολεων πρωτεασης που εξαρτωνται απο το κυτοχρωμα ρ450
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
CY1110259T1 (el) Ανοσορυθμιστης
BR0215405A (pt) Composições e processos de uso de collajolie
ATE507839T1 (de) Kombinationstherapie
CY1114554T1 (el) Ινδαζολια, βενζοτριαζολια και ν-αναλογα αυτων ως αναστολεις p38 κινασης
IL156774A0 (en) Inhibitors of cruzipain and other cysteine proteases
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
BR9809185A (pt) Diidropiranos fundidos
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd